Cargando…
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
[Image: see text] Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for in vivo applications. Particularly, miR-200c-3p is a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436244/ https://www.ncbi.nlm.nih.gov/pubmed/37549382 http://dx.doi.org/10.1021/acsami.3c07541 |
_version_ | 1785092279741972480 |
---|---|
author | Garrido-Cano, Iris Adam-Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela-Noguera, Vicente Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez-Máñez, Ramón Eroles, Pilar |
author_facet | Garrido-Cano, Iris Adam-Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela-Noguera, Vicente Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez-Máñez, Ramón Eroles, Pilar |
author_sort | Garrido-Cano, Iris |
collection | PubMed |
description | [Image: see text] Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for in vivo applications. Particularly, miR-200c-3p is a well-known tumor suppressor microRNA that inhibits tumor progression and metastasis in breast cancer through downregulating ZEB1 and ZEB2. Based on the above, we describe the design and validation of a nanodevice using mesoporous silica nanoparticles for miR-200c-3p delivery for breast cancer treatment. We demonstrate the biocompatibility of the synthesized nanodevices as well as their ability to escape from endosomes/lysosomes and inhibit tumorigenesis, invasion, migration, and proliferation of tumor cells in vitro. Moreover, tumor targeting and effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mouse model, and the therapeutic efficacy is also evidenced by a decrease in tumor size and lung metastasis, while showing no signs of toxicity. Overall, our results provide evidence that miR-200c-3p-loaded nanoparticles are a potential strategy for breast cancer therapy and a safe and effective system for tumor-targeted delivery of microRNAs. |
format | Online Article Text |
id | pubmed-10436244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-104362442023-08-19 Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy Garrido-Cano, Iris Adam-Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela-Noguera, Vicente Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez-Máñez, Ramón Eroles, Pilar ACS Appl Mater Interfaces [Image: see text] Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for in vivo applications. Particularly, miR-200c-3p is a well-known tumor suppressor microRNA that inhibits tumor progression and metastasis in breast cancer through downregulating ZEB1 and ZEB2. Based on the above, we describe the design and validation of a nanodevice using mesoporous silica nanoparticles for miR-200c-3p delivery for breast cancer treatment. We demonstrate the biocompatibility of the synthesized nanodevices as well as their ability to escape from endosomes/lysosomes and inhibit tumorigenesis, invasion, migration, and proliferation of tumor cells in vitro. Moreover, tumor targeting and effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mouse model, and the therapeutic efficacy is also evidenced by a decrease in tumor size and lung metastasis, while showing no signs of toxicity. Overall, our results provide evidence that miR-200c-3p-loaded nanoparticles are a potential strategy for breast cancer therapy and a safe and effective system for tumor-targeted delivery of microRNAs. American Chemical Society 2023-08-07 /pmc/articles/PMC10436244/ /pubmed/37549382 http://dx.doi.org/10.1021/acsami.3c07541 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Garrido-Cano, Iris Adam-Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela-Noguera, Vicente Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez-Máñez, Ramón Eroles, Pilar Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy |
title | Delivery
of miR-200c-3p
Using Tumor-Targeted Mesoporous
Silica Nanoparticles for Breast Cancer Therapy |
title_full | Delivery
of miR-200c-3p
Using Tumor-Targeted Mesoporous
Silica Nanoparticles for Breast Cancer Therapy |
title_fullStr | Delivery
of miR-200c-3p
Using Tumor-Targeted Mesoporous
Silica Nanoparticles for Breast Cancer Therapy |
title_full_unstemmed | Delivery
of miR-200c-3p
Using Tumor-Targeted Mesoporous
Silica Nanoparticles for Breast Cancer Therapy |
title_short | Delivery
of miR-200c-3p
Using Tumor-Targeted Mesoporous
Silica Nanoparticles for Breast Cancer Therapy |
title_sort | delivery
of mir-200c-3p
using tumor-targeted mesoporous
silica nanoparticles for breast cancer therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436244/ https://www.ncbi.nlm.nih.gov/pubmed/37549382 http://dx.doi.org/10.1021/acsami.3c07541 |
work_keys_str_mv | AT garridocanoiris deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT adamartiguesanna deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT lameirinhasana deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT blandezjuanf deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT candelanogueravicente deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT lluchana deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT bermejobegona deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT sancenonfelix deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT cejalvojuanmiguel deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT martinezmanezramon deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy AT erolespilar deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy |